Sood Neeraj, de Vries Han, Gutierrez Italo, Lakdawalla Darius N, Goldman Dana P
RAND in Santa Monica, California, USA.
Health Aff (Millwood). 2009 Jan-Feb;28(1):w125-37. doi: 10.1377/hlthaff.28.1.w125. Epub 2008 Dec 16.
We describe pharmaceutical regulations in nineteen developed countries from 1992 to 2004 and analyze how different regulations affect pharmaceutical revenues. First, there has been a trend toward increased regulation. Second, most regulations reduce pharmaceutical revenues significantly. Third, since 1994, most countries adopting new regulations already had some regulation in place. We find that incremental regulation of this kind had a smaller impact on costs. However, introducing new regulations in a largely unregulated market, such as the United States, could greatly reduce pharmaceutical revenues. Finally, we show that the cost-reducing effects of price controls increase the longer they remain in place.
我们描述了1992年至2004年期间19个发达国家的药品监管情况,并分析了不同的监管措施如何影响药品收入。首先,监管有加强的趋势。其次,大多数监管措施会显著降低药品收入。第三,自1994年以来,大多数实施新监管措施的国家此前已有一些监管措施。我们发现,这种渐进式监管对成本的影响较小。然而,在一个基本未受监管的市场(如美国)引入新的监管措施,可能会大幅降低药品收入。最后,我们表明,价格管制的成本降低效果会随着其实施时间的延长而增强。